Skip to content
Head to head

Ligand Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: LGND · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

LGND +42.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals trades cheapest on trailing earnings; Vertex Pharmaceuticals earns the most per share.
LGNDVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price286.85515.02
Change today-0.03%-1.08%
1-year return+44.1%+22.0%
Market cap$5.74B$130.58B
52-week range175.89 – 326.63412.27 – 568.67
Valuation
P/E (TTM)115.2033.14
P/E percentile, own 5-yr range99th99th
P/B5.976.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)6.1315.32
Net profit (TTM)$122.62M$3.88B
Revenue (TTM)$253.83M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-31.8%+11.8%
Gross margin95.2%85.5%
Operating margin14.4%33.1%
Net margin20.3%30.7%
Free cash flow (TTM)$57.47M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership117.7%96.8%
Insider activity (12mo)18 buy / 32 sell28 buy / 22 sell
Short interest (% of float)12.4%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$367 (+28%)$624 (+21%)
StockVane view
StockVane Quant RatingC (82)C (68)
Company
Employees476,400
Founded19871989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.